Our top pick for
BeiGene, Ltd is a biotechnology business based in the US. BeiGene shares (BGNE) are listed on the NASDAQ and all prices are listed in US Dollars. BeiGene employs 4,600 staff and has a trailing 12-month revenue of around USD$265.7 million.
|52-week range||USD$118.55 - USD$388.97|
|50-day moving average||USD$337.5644|
|200-day moving average||USD$282.6294|
|Wall St. target price||USD$314.02|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-11.287|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$265.7 million|
|Gross profit TTM||USD$-570,316,000|
|Return on assets TTM||-26.2%|
|Return on equity TTM||-54.22%|
|Market capitalisation||USD$32.1 billion|
TTM: trailing 12 months
There are currently 2.0 million BeiGene shares held short by investors – that's known as BeiGene's "short interest". This figure is 0.4% up from 2.0 million last month.
There are a few different ways that this level of interest in shorting BeiGene shares can be evaluated.
BeiGene's "short interest ratio" (SIR) is the quantity of BeiGene shares currently shorted divided by the average quantity of BeiGene shares traded daily (recently around 377111.11111111). BeiGene's SIR currently stands at 5.4. In other words for every 100,000 BeiGene shares traded daily on the market, roughly 5400 shares are currently held short.
However BeiGene's short interest can also be evaluated against the total number of BeiGene shares, or, against the total number of tradable BeiGene shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BeiGene's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 BeiGene shares in existence, roughly 20 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable BeiGene shares, roughly 0 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against BeiGene.
Find out more about how you can short BeiGene stock.
We're not expecting BeiGene to pay a dividend over the next 12 months.
Over the last 12 months, BeiGene's shares have ranged in value from as little as $118.55 up to $388.97. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BeiGene's is 0.8725. This would suggest that BeiGene's shares are less volatile than average (for this exchange).
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology cancer therapeutics in the People's Republic of China, the United States, and internationally. Its commercial products include BRUKINSA to treat R/R mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; KYPROLIS to treat multiple myeloma; BLINCYTO to treat acute lymphocytic leukemia; SYLVANT to treat idiopathic multicentric castleman disease; and QARZIBA to treat neuroblastoma. The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Pamiparib, an inhibitor of PARP1 and PARP2 to treat various solid tumors; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumor. In addition, its clinical stage drug candidates include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; BGB-A1217, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; and BGB-A445, an OX40 agonist antibody to treat solid tumors. The company has collaborations with Celgene Corporation; Merck KGaA; Mirati Therapeutics, Inc.; BioAtla, LLC; Zymeworks, Inc.; Ambrx, Inc.; Atreca Inc.; IGM Biosciences, Inc.; Hutchison China MediTech Limited; and Novartis. BeiGene, Ltd. was founded in 2010 and is based in Beijing, the People's Republic of China.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.